請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33062完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 蔡錦華(Ching-Hwa Tsa) | |
| dc.contributor.author | Shao-Wen Wu | en |
| dc.contributor.author | 吳韶文 | zh_TW |
| dc.date.accessioned | 2021-06-13T04:23:37Z | - |
| dc.date.available | 2021-07-27 | |
| dc.date.copyright | 2011-10-07 | |
| dc.date.issued | 2011 | |
| dc.date.submitted | 2011-07-27 | |
| dc.identifier.citation | Adamson, A. L., Darr, D., Holley-Guthrie, E., Johnson, R. A., Mauser, A., Swenson, J. & Kenney, S. (2000). Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol 74, 1224-1233.
Adamson, A. L. & Kenney, S. (1999). The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. J Virol 73, 6551-6558. Avalos, B. R., Kaufman, S. E., Tomonaga, M., Williams, R. E., Golde, D. W. & Gasson, J. C. (1988). K562 cells produce and respond to human erythroid-potentiating activity. Blood 71, 1720-1725. Babcock, G. J., Decker, L. L., Volk, M. & Thorley-Lawson, D. A. (1998). EBV persistence in memory B cells in vivo. Immunity 9, 395-404. Babcock, G. J., Hochberg, D. & Thorley-Lawson, A. D. (2000). The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13, 497-506. Baer, R., Bankier, A. T., Biggin, M. D., Deininger, P. L., Farrell, P. J., Gibson, T. J., Hatfull, G., Hudson, G. S., Satchwell, S. C., Seguin, C. & et al. (1984). DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207-211. Bahr, M. J., Vincent, K. J., Arthur, M. J., Fowler, A. V., Smart, D. E., Wright, M. C., Clark, I. M., Benyon, R. C., Iredale, J. P. & Mann, D. A. (1999). Control of the tissue inhibitor of metalloproteinases-1 promoter in culture-activated rat hepatic stellate cells: regulation by activator protein-1 DNA binding proteins. Hepatology 29, 839-848. Bauer, E. A., Stricklin, G. P., Jeffrey, J. J. & Eisen, A. Z. (1975). Collagenase production by human skin fibroblasts. Biochem Biophys Res Commun 64, 232-240. Bellehumeur, C., Collette, T., Maheux, R., Mailloux, J., Villeneuve, M. & Akoum, A. (2005). Increased soluble interleukin-1 receptor type II proteolysis in the endometrium of women with endometriosis. Hum Reprod 20, 1177-1184. Brew, K., Dinakarpandian, D. & Nagase, H. (2000). Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477, 267-283. Brew, K. & Nagase, H. (2010 ). The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803, 55-71. Bruegmann, E., Gruemmer, R., Neulen, J. & Motejlek, K. (2009). Regulation of soluble vascular endothelial growth factor receptor 1 secretion from human endothelial cells by tissue inhibitor of metalloproteinase 1. Mol Hum Reprod 15, 749-756. Burkitt, D. (1962). A tumour syndrome affecting children in tropical Africa. Postgrad Med J 38, 71-79. Campbell, C. E., Flenniken, A. M., Skup, D. & Williams, B. R. (1991). Identification of a serum- and phorbol ester-responsive element in the murine tissue inhibitor of metalloproteinase gene. J Biol Chem 266, 7199-7206. Caterina, N. C., Windsor, L. J., Bodden, M. K., Yermovsky, A. E., Taylor, K. B., Birkedal-Hansen, H. & Engler, J. A. (1998). Glycosylation and NH2-terminal domain mutants of the tissue inhibitor of metalloproteinases-1 (TIMP-1). Biochim Biophys Acta 1388, 21-34. Cawston, T. E., Galloway, W. A., Mercer, E., Murphy, G. & Reynolds, J. J. (1981). Purification of rabbit bone inhibitor of collagenase. Biochem J 195, 159-165. Chang, Y., Lee, H. H., Chang, S. S., Hsu, T. Y., Wang, P. W., Chang, Y. S., Takada, K. & Tsai, C. H. (2004). Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta. J Virol 78, 13028-13036. Chang, Y. N., Dong, D. L., Hayward, G. S. & Hayward, S. D. (1990). The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif. J Virol 64, 3358-3369. Chen, C., Li, D. & Guo, N. (2009). Regulation of cellular and viral protein expression by the Epstein-Barr virus transcriptional regulator Zta: implications for therapy of EBV associated tumors. Cancer Biol Ther 8, 987-995. Chen, M. R., Huang, H., Fen, C. Y. & Chen, J. Y. (2000). A novel EBNA-1 tag system for high level expression and efficient detection of fusion proteins in vitro and in vivo. J Virol Methods 85, 35-41. Chen, M. R., Tsai, C. H., Wu, F. F., Kan, S. H., Yang, C. S. & Chen, J. Y. (1999). The major immunogenic epitopes of Epstein-Barr virus (EBV) nuclear antigen 1 are encoded by sequence domains which vary among nasopharyngeal carcinoma biopsies and EBV-associated cell lines. J Gen Virol 80 ( Pt 2), 447-455. Chen, S. Y., Lu, J., Shih, Y. C. & Tsai, C. H. (2002). Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J Virol 76, 9556-9561. Chesler, L., Golde, D. W., Bersch, N. & Johnson, M. D. (1995). Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 86, 4506-4515. Chevallier-Greco, A., Manet, E., Chavrier, P., Mosnier, C., Daillie, J. & Sergeant, A. (1986). Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. Embo J 5, 3243-3249. Chou, Y. C., Lin, S. J., Lu, J., Yeh, T. H., Chen, C. L., Weng, P. L., Lin, J. H., Yao, M. & Tsai, C. H. (2011). Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus-mediated B cell proliferation. Blood. Clark, I. M., Rowan, A. D., Edwards, D. R., Bech-Hansen, T., Mann, D. A., Bahr, M. J. & Cawston, T. E. (1997). Transcriptional activity of the human tissue inhibitor of metalloproteinases 1 (TIMP-1) gene in fibroblasts involves elements in the promoter, exon 1 and intron 1. Biochem J 324 ( Pt 2), 611-617. Clark, I. M., Swingler, T. E., Sampieri, C. L. & Edwards, D. R. (2008). The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40, 1362-1378. Countryman, J., Jenson, H., Seibl, R., Wolf, H. & Miller, G. (1987). Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol 61, 3672-3679. D'Addario, M., Ahmad, A., Morgan, A. & Menezes, J. (2000). Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the upregulation of the TNF-alpha gene expression in monocytic cells via NF-kappaB involving PKC, PI3-K and tyrosine kinases. J Mol Biol 298, 765-778. D'Addario, M., Ahmad, A., Xu, J. W. & Menezes, J. (1999). Epstein-Barr virus envelope glycoprotein gp350 induces NF-kappaB activation and IL-1beta synthesis in human monocytes-macrophages involving PKC and PI3-K. Faseb J 13, 2203-2213. Dawson, C. W., Tramountanis, G., Eliopoulos, A. G. & Young, L. S. (2003). Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem 278, 3694-3704. Dean, G., Young, D. A., Edwards, D. R. & Clark, I. M. (2000). The human tissue inhibitor of metalloproteinases (TIMP)-1 gene contains repressive elements within the promoter and intron 1. J Biol Chem 275, 32664-32671. Dien, J., Amin, H. M., Chiu, N., Wong, W., Frantz, C., Chiu, B., Mackey, J. R. & Lai, R. (2006). Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol 169, 633-642. Docherty, A. J., Lyons, A., Smith, B. J., Wright, E. M., Stephens, P. E., Harris, T. J., Murphy, G. & Reynolds, J. J. (1985). Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 318, 66-69. Dolyniuk, M., Pritchett, R. & Kieff, E. (1976a). Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol 17, 935-949. Dolyniuk, M., Wolff, E. & Kieff, E. (1976b). Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus. J Virol 18, 289-297. Edwards, D. R., Handsley, M. M. & Pennington, C. J. (2008). The ADAM metalloproteinases. Mol Aspects Med 29, 258-289. Eliopoulos, A. G., Caamano, J. H., Flavell, J., Reynolds, G. M., Murray, P. G., Poyet, J. L. & Young, L. S. (2003). Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway. Oncogene 22, 7557-7569. Eliopoulos, A. G., Gallagher, N. J., Blake, S. M., Dawson, C. W. & Young, L. S. (1999). Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274, 16085-16096. Eliopoulos, A. G., Stack, M., Dawson, C. W., Kaye, K. M., Hodgkin, L., Sihota, S., Rowe, M. & Young, L. S. (1997). Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 14, 2899-2916. Eliopoulos, A. G. & Young, L. S. (2001). LMP1 structure and signal transduction. Semin Cancer Biol 11, 435-444. Epstein, M. A., Henle, G., Achong, B. G. & Barr, Y. M. (1965). Morphological and Biological Studies on a Virus in Cultured Lymphoblasts from Burkitt's Lymphoma. J Exp Med 121, 761-770. ErnbergI, Masucci, G. & Klein, G. (1976). Persistence of Epstein-Barr viral nuclear antigen (EBNA) in cells entering the EB viral cycle. Int J Cancer 17, 197-203. Fahraeus, R., Fu, H. L., Ernberg, I., Finke, J., Rowe, M., Klein, G., Falk, K., Nilsson, E., Yadav, M., Busson, P. & et al. (1988). Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42, 329-338. Fields, J., Gardner-Mercer, J., Borgmann, K., Clark, I. & Ghorpade, A. (2011). CCAAT/enhancer binding protein beta expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1. J Neurochem 118, 93-104. Flenniken, A. M. & Williams, B. R. (1990). Developmental expression of the endogenous TIMP gene and a TIMP-lacZ fusion gene in transgenic mice. Genes Dev 4, 1094-1106. Gasson, J. C., Golde, D. W., Kaufman, S. E., Westbrook, C. A., Hewick, R. M., Kaufman, R. J., Wong, G. G., Temple, P. A., Leary, A. C., Brown, E. L. & et al. (1985). Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature 315, 768-771. Gaudin, P., Trocme, C., Berthier, S., Kieffer, S., Boutonnat, J., Lamy, C., Surla, A., Garin, J. & Morel, F. (2000). TIMP-1/MMP-9 imbalance in an EBV-immortalized B lymphocyte cellular model: evidence for TIMP-1 multifunctional properties. Biochim Biophys Acta 1499, 19-33. Gewies, A. (2003). Introduction to Apoptosis. ApoReview, 1-26. Gires, O., Kohlhuber, F., Kilger, E., Baumann, M., Kieser, A., Kaiser, C., Zeidler, R., Scheffer, B., Ueffing, M. & Hammerschmidt, W. (1999). Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. Embo J 18, 3064-3073. Given, D. & Kieff, E. (1979). DNA of Epstein-Barr virus. VI. Mapping of the internal tandem reiteration. J Virol 31, 315-324. Greene, J., Wang, M., Liu, Y. E., Raymond, L. A., Rosen, C. & Shi, Y. E. (1996). Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 271, 30375-30380. Greenspan, J. S., Greenspan, D., Lennette, E. T., Abrams, D. I., Conant, M. A., Petersen, V. & Freese, U. K. (1985). Replication of Epstein-Barr virus within the epithelial cells of oral 'hairy' leukoplakia, an AIDS-associated lesion. N Engl J Med 313, 1564-1571. Guedez, L., Stetler-Stevenson, W. G., Wolff, L., Wang, J., Fukushima, P., Mansoor, A. & Stetler-Stevenson, M. (1998). In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102, 2002-2010. Hardwick, J. M., Lieberman, P. M. & Hayward, S. D. (1988). A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol 62, 2274-2284. Havelka, A. M., Berndtsson, M., Olofsson, M. H., Shoshan, M. C. & Linder, S. (2007). Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an 'off-target' effect? Mini Rev Med Chem 7, 1035-1039. Hayakawa, T., Yamashita, K., Tanzawa, K., Uchijima, E. & Iwata, K. (1992). Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298, 29-32. Heaney, M. L. & Golde, D. W. (1998). Soluble receptors in human disease. J Leukoc Biol 64, 135-146. Henderson, S., Rowe, M., Gregory, C., Croom-Carter, D., Wang, F., Longnecker, R., Kieff, E. & Rickinson, A. (1991). Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65, 1107-1115. Henle, G. & Henle, W. (1966). Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 91, 1248-1256. Horikawa, T., Yoshizaki, T., Sheen, T. S., Lee, S. Y. & Furukawa, M. (2000). Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 89, 715-723. Hsu, T. Y., Chang, Y., Wang, P. W., Liu, M. Y., Chen, M. R., Chen, J. Y. & Tsai, C. H. (2005). Reactivation of Epstein-Barr virus can be triggered by an Rta protein mutated at the nuclear localization signal. J Gen Virol 86, 317-322. Huang, Y. T., Liu, M. Y., Tsai, C. H. & Yeh, T. H. (2010). Upregulation of interleukin-1 by Epstein-Barr virus latent membrane protein 1 and its possible role in nasopharyngeal carcinoma cell growth. Head Neck 32, 869-876. Huen, D. S., Henderson, S. A., Croom-Carter, D. & Rowe, M. (1995). The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10, 549-560. Izumi, K. M. & Kieff, E. D. (1997). The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci U S A 94, 12592-12597. Jackson, L., Cady, C. T. & Cambier, J. C. (2009). TLR4-mediated signaling induces MMP9-dependent cleavage of B cell surface CD23. J Immunol 183, 2585-2592. Johansson, B., Klein, G., Henle, W. & Henle, G. (1970). Epstein-Barr virus (EBV)-associated antibody patterns in malignant lymphoma and leukemia. I. Hodgkin's disease. Int J Cancer 6, 450-462. Joseph, A. M., Babcock, G. J. & Thorley-Lawson, D. A. (2000). Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 74, 9964-9971. Khan, G., Miyashita, E. M., Yang, B., Babcock, G. J. & Thorley-Lawson, D. A. (1996). Is EBV persistence in vivo a model for B cell homeostasis? Immunity 5, 173-179. Klein, G., Clifford, P., Henle, G., Henle, W., Geering, G. & Old, L. J. (1969). EBV-associated serological patterns in a Burkitt lymphoma patient during regression and recurrence. Int J Cancer 4, 416-421. Klein, G., Giovanella, B., Westman, A., Stehlin, J. S. & Mumford, D. (1975). An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 5, 319-334. Klein, S. C., Kube, D., Abts, H., Diehl, V. & Tesch, H. (1996). Promotion of IL8, IL10, TNF alpha and TNF beta production by EBV infection. Leuk Res 20, 633-636. Kopitz, C., Gerg, M., Bandapalli, O. R., Ister, D., Pennington, C. J., Hauser, S., Flechsig, C., Krell, H. W., Antolovic, D., Brew, K., Nagase, H., Stangl, M., von Weyhern, C. W., Brucher, B. L., Brand, K., Coussens, L. M., Edwards, D. R. & Kruger, A. (2007). Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 67, 8615-8623. Kouzarides, T., Packham, G., Cook, A. & Farrell, P. J. (1991). The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene 6, 195-204. Kuettner, K. E., Hiti, J., Eisenstein, R. & Harper, E. (1976). Collagenase inhibition by cationic proteins derived from cartilage and aorta. Biochem Biophys Res Commun 72, 40-46. Laherty, C. D., Hu, H. M., Opipari, A. W., Wang, F. & Dixit, V. M. (1992). The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 267, 24157-24160. Lambert, E., Dasse, E., Haye, B. & Petitfrere, E. (2004). TIMPs as multifacial proteins. Crit Rev Oncol Hematol 49, 187-198. Logan, S. K., Garabedian, M. J., Campbell, C. E. & Werb, Z. (1996). Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors. J Biol Chem 271, 774-782. Lotz, M. & Guerne, P. A. (1991). Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). J Biol Chem 266, 2017-2020. Lu, J., Chua, H. H., Chen, S. Y., Chen, J. Y. & Tsai, C. H. (2003). Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res 63, 256-262. Maier, R., Ganu, V. & Lotz, M. (1993). Interleukin-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of metalloproteinases. J Biol Chem 268, 21527-21532. McColl, S. R., Roberge, C. J., Larochelle, B. & Gosselin, J. (1997). EBV induces the production and release of IL-8 and macrophage inflammatory protein-1 alpha in human neutrophils. J Immunol 159, 6164-6168. Menezes, J., Leibold, W., Klein, G. & Clements, G. (1975). Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 22, 276-284. Miller, G., Himmelfarb, H., Heston, L., Countryman, J., Gradoville, L., Baumann, R., Chi, T. & Carey, M. (1993). Comparing regions of the Epstein-Barr virus ZEBRA protein which function as transcriptional activating sequences in Saccharomyces cerevisiae and in B cells. J Virol 67, 7472-7481. Mogensen, T. H. & Paludan, S. R. (2001). Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev 65, 131-150. Mohammed, F. F., Pennington, C. J., Kassiri, Z., Rubin, J. S., Soloway, P. D., Ruther, U., Edwards, D. R. & Khokha, R. (2005). Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology 41, 857-867. Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C. & Kieff, E. (1995). The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80, 389-399. Murphy, G. & Nagase, H. (2008). Progress in matrix metalloproteinase research. Mol Aspects Med 29, 290-308. Nagase, H., Visse, R. & Murphy, G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69, 562-573. Nagase, H. & Woessner, J. F., Jr. (1999). Matrix metalloproteinases. J Biol Chem 274, 21491-21494. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M. & Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267. Oelmann, E., Herbst, H., Zuhlsdorf, M., Albrecht, O., Nolte, A., Schmitmann, C., Manzke, O., Diehl, V., Stein, H. & Berdel, W. E. (2002). Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells. Blood 99, 258-267. Parkin, D. M., Stjernsward, J. & Muir, C. S. (1984). Estimates of the worldwide frequency of twelve major cancers. Bull World Health Organ 62, 163-182. Pavloff, N., Staskus, P. W., Kishnani, N. S. & Hawkes, S. P. (1992). A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J Biol Chem 267, 17321-17326. Pearson, G. R., Vroman, B., Chase, B., Sculley, T., Hummel, M. & Kieff, E. (1983). Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. J Virol 47, 193-201. Pohar, N., Godenschwege, T. A. & Buchner, E. (1999). Invertebrate tissue inhibitor of metalloproteinase: structure and nested gene organization within the synapsin locus is conserved from Drosophila to human. Genomics 57, 293-296. Pope, J. H., Horne, M. K. & Scott, W. (1968). Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer 3, 857-866. Porter, S., Clark, I. M., Kevorkian, L. & Edwards, D. R. (2005). The ADAMTS metalloproteinases. Biochem J 386, 15-27. Rickinson, A. B. & Kieff, E. (2007). Epstein-Barr virus-associated malignancies of the immunocompromised host. In Fields Virology, 5 edn, pp. 2668-2700. Edited by D. M. K. a. P. M. Howley: Lippincott Williams & Wilkins. Roberge, C. J., Larochelle, B., Rola-Pleszczynski, M. & Gosselin, J. (1997). Epstein-Barr virus induces GM-CSF synthesis by monocytes: effect on EBV-induced IL-1 and IL-1 receptor antagonist production in neutrophils. Virology 238, 344-352. Roberge, C. J., Poubelle, P. E., Beaulieu, A. D., Heitz, D. & Gosselin, J. (1996). The IL-1 and IL-1 receptor antagonist (IL-1Ra) response of human neutrophils to EBV stimulation. Preponderance of IL-Ra detection. J Immunol 156, 4884-4891. Roy, R., Yang, J. & Moses, M. A. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27, 5287-5297. Sampieri, C. L., Nuttall, R. K., Young, D. A., Goldspink, D., Clark, I. M. & Edwards, D. R. (2008). Activation of p38 and JNK MAPK pathways abrogates requirement for new protein synthesis for phorbol ester mediated induction of select MMP and TIMP genes. Matrix Biol 27, 128-138. Sato, T., Ito, A. & Mori, Y. (1990). Interleukin 6 enhances the production of tissue inhibitor of metalloproteinases (TIMP) but not that of matrix metalloproteinases by human fibroblasts. Biochem Biophys Res Commun 170, 824-829. Sato, T., Koike, L., Miyata, Y., Hirata, M., Mimaki, Y., Sashida, Y., Yano, M. & Ito, A. (2002). Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res 62, 1025-1029. Shimizu, N., Tanabe-Tochikura, A., Kuroiwa, Y. & Takada, K. (1994). Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 68, 6069-6073. Sixbey, J. W., Vesterinen, E. H., Nedrud, J. G., Raab-Traub, N., Walton, L. A. & Pagano, J. S. (1983). Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature 306, 480-483. Sohara, N., Trojanowska, M. & Reuben, A. (2002). Oncostatin M stimulates tissue inhibitor of metalloproteinase-1 via a MEK-sensitive mechanism in human myofibroblasts. J Hepatol 36, 191-199. Stetler-Stevenson, M., Mansoor, A., Lim, M., Fukushima, P., Kehrl, J., Marti, G., Ptaszynski, K., Wang, J. & Stetler-Stevenson, W. G. (1997). Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood 89, 1708-1715. Suryadevara, R., Holter, S., Borgmann, K., Persidsky, R., Labenz-Zink, C., Persidsky, Y., Gendelman, H. E., Wu, L. & Ghorpade, A. (2003). Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia 44, 47-56. Tanner, J. E., Alfieri, C., Chatila, T. A. & Diaz-Mitoma, F. (1996). Induction of interleukin-6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220. J Virol 70, 570-575. Taube, M. E., Liu, X. W., Fridman, R. & Kim, H. R. (2006). TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein. Oncogene 25, 3041-3048. Thorley-Lawson, D. A. & Babcock, G. J. (1999). A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci 65, 1433-1453. Toi, M., Ishigaki, S. & Tominaga, T. (1998). Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat 52, 113-124. Tsai, C. H., Liu, M. T., Chen, M. R., Lu, J., Yang, H. L., Chen, J. Y. & Yang, C. S. (1997). Characterization of Monoclonal Antibodies to the Zta and DNase Proteins of Epstein-Barr Virus. J Biomed Sci 4, 69-77. Tsai, S. C., Lin, S. J., Chen, P. W., Luo, W. Y., Yeh, T. H., Wang, H. W., Chen, C. J. & Tsai, C. H. (2009). EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines. Blood 114, 109-118. Uchijima, M., Sato, H., Fujii, M. & Seiki, M. (1994). Tax proteins of human T-cell leukemia virus type 1 and 2 induce expression of the gene encoding erythroid-potentiating activity (tissue inhibitor of metalloproteinases-1, TIMP-1). J Biol Chem 269, 14946-14950. Vater, C. A., Mainardi, C. L. & Harris, E. D., Jr. (1979). Inhibitor of human collagenase from cultures of human tendon. J Biol Chem 254, 3045-3053. Wang, F., Gregory, C., Sample, C., Rowe, M., Liebowitz, D., Murray, R., Rickinson, A. & Kieff, E. (1990). Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64, 2309-2318. Wang, H., Jing, Y., Zheng, J. & Wang, M. (2010). [Expression of MMP-9 and TIMP-1 in nasopharyngeal carcinoma and its signification at Xi'an and Shenzhen]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 24, 296-298. Wang, T., Yamashita, K., Iwata, K. & Hayakawa, T. (2002). Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways. Biochem Biophys Res Commun 296, 201-205. Welgus, H. G., Stricklin, G. P., Eisen, A. Z., Bauer, E. A., Cooney, R. V. & Jeffrey, J. J. (1979). A specific inhibitor of vertebrate collagenase produced by human skin fibroblasts. J Biol Chem 254, 1938-1943. Woolley, D. E., Roberts, D. R. & Evanson, J. M. (1975). Inhibition of human collagenase activity by a small molecular weight serum protein. Biochem Biophys Res Commun 66, 747-754. Wright, J. K., Clark, I. M., Cawston, T. E. & Hazleman, B. L. (1991). The secretion of the tissue inhibitor of metalloproteinases (TIMP) by human synovial fibroblasts is modulated by all-trans-retinoic acid. Biochim Biophys Acta 1133, 25-30. Yamashita, K., Suzuki, M., Iwata, H., Koike, T., Hamaguchi, M., Shinagawa, A., Noguchi, T. & Hayakawa, T. (1996). Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). FEBS Lett 396, 103-107. Yates, J. L., Warren, N. & Sugden, B. (1985). Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313, 812-815. Yi, S. X. & Lee, R. E., Jr. (2011). Rapid cold-hardening blocks cold-induced apoptosis by inhibiting the activation of pro-caspases in the flesh fly Sarcophaga crassipalpis. Apoptosis 16, 249-255. Yoshida, M. & Seiki, M. (1987). Recent advances in the molecular biology of HTLV-1: trans-activation of viral and cellular genes. Annu Rev Immunol 5, 541-559. Yoshizaki, T., Sato, H., Murono, S., Pagano, J. S. & Furukawa, M. (1999). Matrix metalloproteinase 9 is induced by the Epstein-Barr virus BZLF1 transactivator. Clin Exp Metastasis 17, 431-436. Young, L. S. & Murray, P. G. (2003). Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22, 5108-5121. Young, L. S. & Rowe, M. (1992). Epstein-Barr virus, lymphomas and Hodgkin's disease. Semin Cancer Biol 3, 273-284. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15, 871-875. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33062 | - |
| dc.description.abstract | EB病毒 (Epstein-Barr virus)是一廣泛流行的人類皰疹病毒，主要感染淋巴細胞與上皮細胞。臨床上，多種與EB病毒有高度相關性的疾病都具有淋巴球浸潤以及病變組織細胞含有大量細胞激素的特徵。已知，EB病毒感染細胞後可利用多種策略調控細胞激素表現量，以利於病毒基因體複製或宿主細胞存活。在本實驗室先前的cDNA微陣列分析以及細胞激素蛋白質微陣列分析中，發現受EB病毒感染之B細胞其基質金屬蛋白酶組織抑制因子 (tissue inhibitor of metalloproteinase-1，TIMP-1)表現量有明顯增加的現象。TIMP-1在許多預後較差的癌症病患檢體中可以偵測到高量表現，被認為可當作部分癌症的預後指標。因此，本研究進一步探討EB病毒感染細胞後誘發TIMP-1表現之調控機制和生物功能。
首先，以RT-Q-PCR和ELISA實驗證實，EB病毒在感染B細胞初期即可促進細胞內TIMP-1 mRNA轉錄及蛋白質分泌至細胞外，而且TIMP-1的高表現量可以持續至B細胞被EB病毒轉形成具有不斷增生能力的淋巴母芽細胞 (lymphoblastoid cell line，LCL)。而在細胞內轉染EB病毒基因後，可觀察到EB病毒溶裂期轉錄活化因子Zta在人類上皮細胞HEK293T、RHEK和多種柏金氏淋巴瘤 (Burkitt’s lymphoma)細胞株內都具有誘發TIMP-1基因表現的能力，在部分柏金氏淋巴瘤細胞株中則發現Zta和潛伏膜蛋白質LMP1可協同調控TIMP-1 mRNA表現。此外，在LCL細胞內以shRNA方式分別降解Zta和LMP1 mRNA後，TIMP-1的mRNA轉錄量皆有明顯下降情形，顯示EB病毒可藉由Zta和LMP1促進TIMP-1基因轉錄。分子機制上，經螢光酵素報導基因分析、電泳位移分析和染色質免疫沉澱法，證明Zta是藉由直接結合至TIMP-1啟動子+45 nt位置之AP-1 DNA結合位以促進TIMP-1 mRNA的轉錄活性；利用LMP1刪除圖變型質體則可知，LMP1會透過其C端活化區域CTAR1及CTAR2 domain調控TIMP-1基因表現。進一步探討TIMP-1之生物功能，利用西方墨點法分析可知，LCL內的TIMP-1可抵抗cisplatin和冷刺激誘發之細胞凋亡現象。另一方面，利用人類水溶性受體微陣列分析發現，LCL細胞內的TIMP-1經shRNA降解後會影響細胞培養液中多種水溶性受體的含量，推測TIMP-1是藉由直接影響水溶性受體表現或者藉由其基質金屬酶抑制活性間接調控水溶性受體的含量。 本研究證實，EB病毒在感染細胞後會經由Zta和LMP1協同促進TIMP-1基因轉錄，其中，Zta是藉由直接結合至TIMP-1啟動子以活化其基因表現。而EB病毒感染細胞後誘發TIMP-1生成可幫助細胞抵抗惡劣環境所誘發之細胞凋亡現象以及影響宿主細胞的水溶性受體表現。 | zh_TW |
| dc.description.abstract | Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus mainly infected lymphoid and epithelial cells, and associated with diseases which are characterized by intensive lymphocytes infiltration and cytokines production. EBV infection can manipulate host cytokines production to promote virus replication and cell survival. Using cDNA microarray and cytokine antibody arrays, we found that tissue inhibitor of metalloproteinase-1 (TIMP-1) is induced in B cells after EBV infection. TIMP-1 is reported as a potential prognosis marker in numerous cancers, but its regulatory mechanism and biological function in EBV-infected cells are remaining unclear.
We reveal here that TIMP-1 transcription and translation are induced immediately after EBV infection and maintain high expression level in EBV-immortalized lymphoblastoid cell line (LCL). Furthermore, EBV lytic protein, Zta, which is a key transactivator, is able to induce TIMP-1 expression in epithelial cells and B cells. Besides, EBV LMP1 can synergistic with Zta to regulate TIMP-1 production in some Burkitt’s lymphoma cell lines. Knockdown of Zta and LMP1 with shRNA both decrease TIMP-1 mRNA level in LCLs. The mechanistically underling Zta-mediated induction of TIMP-1 is through direct binding of Zta to the TIMP-1 promoter, via a consensus AP-1 binding site. Deletion of LMP1 activation domain, CTAR1 and CTAR2, abolishes LMP1-mediated induction of TIMP-1, suggesting that both CTAR domains are important for TIMP-1 induction. TIMP-1 is resistance to cisplatin and cold shock induced apoptosis in LCLs. Otherwise, the expression profiles of soluble receptors analyzed by Human soluble receptor array indicates that TIMP-1 can influence soluble receptors expressed and released by LCLs. Our data demonstrate that Zta- and LMP1-induced TIMP-1 production exhibits abilities to resist apoptosis and manipulate soluble receptors expression in EBV-infected B cells, and may contribute to the pathogenesis of EBV-associated lymphoproliferative disease. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T04:23:37Z (GMT). No. of bitstreams: 1 ntu-100-R98445104-1.pdf: 2726985 bytes, checksum: caf23c8a188611c492985276f7d55744 (MD5) Previous issue date: 2011 | en |
| dc.description.tableofcontents | 口試委員審定書 I
致謝 II 中文摘要 III 英文摘要 V 第一章 序論 1 第二章 實驗材料與方法 14 第三章 實驗結果 35 第四章 討論 46 第五章 圖表 52 第六章 參考文獻 74 | |
| dc.language.iso | zh-TW | |
| dc.subject | 水溶性受體 | zh_TW |
| dc.subject | EB病毒 | zh_TW |
| dc.subject | TIMP-1 | zh_TW |
| dc.subject | Zta | zh_TW |
| dc.subject | LMP1 | zh_TW |
| dc.subject | 細胞凋亡 | zh_TW |
| dc.subject | soluble receptor | en |
| dc.subject | EBV | en |
| dc.subject | TIMP-1 | en |
| dc.subject | Zta | en |
| dc.subject | LMP1 | en |
| dc.subject | apoptosis | en |
| dc.title | 探討細胞激素TIMP-1於EB病毒感染B細胞中
之調控機制及生理功能 | zh_TW |
| dc.title | Regulatory Mechanism and Functional Study of TIMP-1 in EBV-infected B Cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 99-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林素珍,董馨蓮 | |
| dc.subject.keyword | EB病毒,TIMP-1,Zta,LMP1,細胞凋亡,水溶性受體, | zh_TW |
| dc.subject.keyword | EBV,TIMP-1,Zta,LMP1,apoptosis,soluble receptor, | en |
| dc.relation.page | 86 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2011-07-27 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-100-1.pdf 未授權公開取用 | 2.66 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。